


# Vanderbilt Mouse Metabolic Phenotyping Center

<http://www.mc.vanderbilt.edu/MMPC>  
twitter: @mousecentral



## Staying Ahead of the Curve and Adding Value to the Program:

- Standardize
- “Brand”
- Innovate
- Education and Outreach



# **MMPC Executive Committee**

Director: David H. Wasserman, PhD


Associate Director: Owen P. McGuinness, PhD

Administrator and AP Guru: \*\*Fran Tripp\*\*

Executive Committee: Cone, Harris, Harrison,  
Magnuson, Peek, Powers



# Cores and Subcores of the MMPC



## \*\*A New Policy\*\*

- Vandy now allows the MMPC to offset the added cost to outside investigators due to shipping, serology, quarantine.
- Outside investigators that request services that are of particular interest to our MMPC will be granted an “MMPC Scholarship”.

# Metabolic Pathophysiology Core (MPC)

Director: Owen P. McGuinness, PhD

Associate Director: Kate Ellacott, PhD

Managing Director: Li Kang, PhD



# About Our New MMPC Laboratory...

## One Important Step Closer



# Procedures/services

- Telemetry (e.g. Temperature)
- **Energy balance (activity, food intake, EE)**
- **Urine and blood analysis**
- **Surgical procedures**
  - Catheterizations
  - Bariatric surgery



# Procedures

- **Glucose tolerance test**
- **Clamps**
- Metabolic flux during exercise
- Circadian rhythm cycles **\*\*new\*\***

# MPC Subcores

## Imaging

- Director: Dave Piston PhD
- Associate Director: Sam Wells PhD



## Islet Isolation (DRTC)

- Director: Marcella Brissova, PhD

## Bariatric Surgery (DRTC, DDRC)

- Director: Dengping Yin, MD PhD




# Cardiovascular Pathophysiology and Complications Core

Director: Chee Lim, PhD

Consulting Director: Jeff Rottman, MD

Associate Director: MacRae Linton, MD



# Principal Services

- **Echocardiography**
- **Invasive and non-invasive measurements of BP**
- Exercise capacity
- **Telemetry and electrocardiography**
- **Myocardial infarct**
- Tissue O<sub>2</sub>, N<sub>2</sub>, diffusivity, blood flow *\*\*new\*\**
- Surgical models

# Analytical Core

Director: Sergio Fazio, MD

- Hormone Assay and Analytical Services (Edgerton/Snead)
- Lipids, Lipoproteins, and Atherosclerosis (Swift)
- Mouse Pathology (Boyd)



# Gross Income

<b>Core</b>	<b>6/1/11 to 5/31/12</b>	<b>6/1/12 to 5/31/13</b>	<b>6/1/13 to 5/31/14**</b>
	Dollars		
MPC	243,181	239,626	232,411
CPCC	201,390	239,845	231,077
ARC	196,692	185,360	210,648
<b>Total</b>	<b>641,263</b>	<b>664,831</b>	<b>674,136</b>

\*\*Projected

# Usage

Core	6/1/11 to 5/31/12	6/1/12 to 5/31/13	6/1/13 to 5/31/14**
	Local/Outside		
MPC Users	165/40	150/61	182/62
MPC Services	7608/2564	5949/2429	6143/2409
CPCC Users	120/22	75/12	87/17
CPCC Services	3523/265	3171/432	3213/773
ARC Users	150/105	108/164	104/99
ARC Services	30568/5396	9102/6762	11901/5979
<b>Pharma/Biotech:</b>	Eli Lily, GSK, Pfizer, BMS, Halozyme, Imclone, Incyte, Genentech, Diamedica, Regeneron		
**annualized			

# *Necessity is the Mother of Invention*

Metabolic Flux and Metabolomics

\*\**new*\*\*

Wasserman/Young Laboratories

Clinton Hasenour PhD (expected Jan 2014)

Emerson Ridley

Martha Wall

Jamey Young PhD (Chem Eng)



# Analytical Core

Metabolic Flux and Metabolomics

*\*\*new\*\**

Developed by:


Clinton Hasenour PhD (expected Jan 2014)

Emerson Ridley



Jamey Young PhD (Chem Eng)




# Experimental Approach for [ $^{13}\text{C}_3$ ]Propionate, [ $6,6^2\text{H}_2$ ]Glucose and $^2\text{H}_2\text{O}$ studies



# Experimental Approach for [ $^{13}\text{C}_3$ ]Propionate, [ $6,6^{2}\text{H}_2$ ]Glucose and $^{2}\text{H}_2\text{O}$ studies






## Measuring Deuterium Enrichment of Glucose Hydrogen Atoms by Gas Chromatography/Mass Spectrometry


Maciek R. Antoniewicz,<sup>†</sup> Joanne K. Kelleher, and Gregory Stephanopoulos<sup>\*</sup>

Department of Chemical Engineering, Bioinformatics and Metabolic Engineering Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States

## S Supporting Information



# Glucose Fragment Enrichment



Results are means  $\pm$  SD

# Results


## *Hasenour & Young Method*

Modeling:		t=190, 200, 210 Time points			
Mouse	LA109-8	EndoRa	13.6	ng/kg/min	
Wt(kg)	0.0251		1.9	μmol/min	
[6,6D2]Glucose Rate	0.8	mg/kg/min	Relative Fluxes		Absolute Flux Rates
Reaction	Equation	Value	StdE	39:8 μmol/min	Error
<b>Absolute flux (μmol/min)</b>		<b>This study (n=5)</b>		<b>Satapati et al. (n=6-8)</b>	
EGP (v1)		1.79 ± 0.16		2.3 ± 0.1	
Glycogenolysis (v2)		0.00 ± 0.00		0.02 ± 0.04	
GNG <sub>glycerol</sub> (v3)		0.55 ± 0.06		0.68 ± 0.05	
GNG <sub>PEP</sub> (v4)		1.24 ± 0.10		1.61 ± 0.06	
Pyruvate cycling (v5)		4.64 ± 0.61		5.31 ± 0.55	
Cataplerosis (v6)		5.29 ± 0.65		8.54 ± 0.63	
CAC flux (v7)		1.82 ± 0.24		1.95 ± 0.15	
Hinf	H.inf → H	64.1	6.5	1.17	0.10
Hsink	H → Sink	557.7	24.0	10.16	0.40

# Results

## *Hasenour and Colleagues*

From Burgess et al.



Fast Duration	9 hr		20 hr		
	Mean	SEM	Mean	SEM	
EndoRa	v1	2.29	0.09	1.85	0.06
Glycogen	v2	0.73	0.06	0.06	0.02
Glycerol	v3	0.18	0.05	0.46	0.04
PEP	v4	1.38	0.06	1.33	0.05
Pyr Cycling	v5	4.99	0.46	5.23	0.40
Anaplerosis	v6	5.59	0.49	5.89	0.41
TCA	v7	2.27	0.16	1.80	0.12

# Big Advantages

1. Small blood volumes allowing for multiple measurements.
2. No requirement for ultra high-end equipment.
3. Shorter run time.
4. Flexible system.
5. Modeling Assumptions = NMR Method making results comparable.

# Immediate Goals

1. Validate with liver specific PEPCK-C knockout (Young, MicroMouse).
2. Set up new GC/MS in Analytical Core
3. Turn key Calculations



# Vanderbilt Summer Research Education Program in Diabetes

- *Glucose Clamping the Conscious Mouse*
- *An Organ Systems Approach to Experimental Targeting of the Metabolic Syndrome\*\**
- *Experimental Techniques in Mouse Kidney Injury Workshop*



# GCCM Class of 2013

18 Registrants:

1 NIH

2 Industry

15 Academic

(5 nonUS/13 US)




Coming Soon!!

Vanderbilt MMPC

*Glucose Clamping the Conscious Mouse*  
September 2014



me with #10  
45 years later



Ron Santo #10 was diagnosed with T1DM at 18 yr of age and had a Hall of Fame career. He raised millions of dollars for diabetes research during his life.